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iabetes is defined by its association with hyperglycemia-
pecific microvascular complications; however, it also im-
arts a two- to fourfold risk of cardiovascular disease
CVD). Although microvascular complications can lead to
ignificant morbidity and premature mortality, by far the
reatest cause of death in people with diabetes is CVD.
Results from randomized controlled trials have demon-
trated conclusively that the risk of microvascular compli-
ations can be reduced by intensive glycemic control in
atients with type 1 (1,2) and type 2 diabetes (3–5). In the
iabetes Control and Complications Trial (DCCT), there
as an 60% reduction in development or progression of
iabetic retinopathy, nephropathy, and neuropathy between
he intensively treated group (goal A1C 6.05%, mean
chieved A1C 7%) and the standard group (A1C 9%)
ver an average of 6.5 years. The relationship between
lucose control (as reflected by the mean on-study A1C
alue) and risk of complications was log-linear and extended
own to the normal A1C range (6%) with no threshold
oted.
In the UK Prospective Diabetes Study (UKPDS), partic-
ipants newly diagnosed with type 2 diabetes were followed
for 10 years, and intensive control (median A1C 7.0%) was
found to reduce the overall microvascular complication rate
by 25% compared with conventional treatment (median
A1C 7.9%). Here, too, secondary analyses showed a con-
tinuous relationship between the risk of microvascular
complications and glycemia extending into the normal
range of A1C, with no glycemic threshold.
On the basis of these two large controlled trials, along
with smaller studies and numerous epidemiologic reports,
the consistent findings related to microvascular risk reduc-
tion with intensive glycemic control have led the American
Diabetes Association (ADA) to recommend an A1C goal of
7% for most adults with diabetes (6), recognizing that
more or less stringent goals may be appropriate for certain
patients. Whereas many epidemiologic studies and meta-
analyses (7,8) have clearly shown a direct relationship
between A1C and CVD, the potential of intensive glycemic
control to reduce CVD events has been less clearly defined.
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January 20, 2009:298–304 Glycemic Control and the Prevention of Cardiovascular Eventsn the DCCT, there was a trend toward lower risk of CVD
vents with intensive control (risk reduction 41% [95% CI
0–68]), but the number of events was small. However,
-year post-DCCT follow-up of the cohort has shown that
articipants previously randomized to the intensive arm had
42% reduction (P  0.02) in CVD outcomes and a 57%
eduction (P  0.02) in the risk of nonfatal myocardial
nfarction (MI), stroke, or CVD death compared with those
reviously in the standard arm (9).
The UKPDS of type 2 diabetes observed a 16% reduction
n cardiovascular complications (combined fatal or nonfatal
I and sudden death) in the intensive glycemic control
rm, although this difference was not statistically significant
P 0.052), and there was no suggestion of benefit on other
VD outcomes such as stroke. However, in an epidemio-
ogic analysis of the study cohort, a continuous association
as observed such that for every percentage point of lower
edian on-study A1C (e.g., 8–7%) there was a statistically
ignificant 18% reduction in CVD events, again with no
lycemic threshold.
Because of ongoing uncertainty regarding whether inten-
ive glycemic control can reduce the increased risk of CVD
n people with type 2 diabetes, several large long-term trials
ere launched in the past decade to compare the effects of
ntensive versus standard glycemic control on CVD out-
omes in relatively high-risk participants with established
ype 2 diabetes. In 2008, two of these trials, Action in
iabetes and Vascular Disease—Preterax and Diamicron
odified Release Controlled Evaluation (ADVANCE) and
he Veterans Affairs Diabetes Trial (VADT), were com-
leted and showed no significant reduction in cardiovascular
utcomes with intensive glycemic control. A third trial,
ction to Control Cardiovascular Risk in Diabetes (AC-
ORD), terminated its glycemic control study early due to
he finding of increased mortality in participants random-
zed to a strategy of very intensive glycemic control with a
arget A1C of6%. The findings of these three major trials
ed the ADA, with representatives of the American Heart
ssociation (AHA) and the American College of Cardiol-
gy Foundation (ACCF), to reexamine the recommenda-
ions for glycemic targets in patients with diabetes, the
ajority of whom have type 2 diabetes.
hat Did the ACCORD, ADVANCE, and
A Diabetes Trials Show?
able 1 provides a summary of baseline characteristics,
lycemic treatment strategies and goals, concomitant risk
actor control, achieved glycemic control, and primary
esults of each of the three studies. The ACCORD study
andomized 10,251 participants with either history of a
VD event (aged 40–79 years) or significant CVD risk
aged 55–79 years with anatomical CVD, albuminuria, left
entricular hypertrophy, or at least two other CVD risk
actors) to a strategy of intensive glycemic control (target
1C 6.0%) or standard glycemic control (target A1C
.0–7.9%). Investigators used multiple glycemic medica- Aions in both arms. ACCORD participants were on average
2 years of age and had a mean duration of diabetes of 10
ears, with 35% already treated with insulin at baseline.
rom a baseline median A1C of 8.1%, the intensive arm
eached a median A1C of 6.4% within 12 months of
andomization, while the standard group reached a median
1C of 7.5%. Other risk factors were treated aggressively
nd equally in both groups. The intensive glycemic control
roup had more use of insulin in combination with multiple
ral agents, significantly more weight gain, and more
pisodes of severe hypoglycemia than the standard group.
In February 2008, the glycemic control study of AC-
ORD was halted (embedded blood pressure and lipid
tudies are ongoing) on the recommendation of the study’s
ata safety monitoring board due to the finding of an
ncreased rate of mortality in the intensive arm compared
ith the standard arm (1.41 vs. 1.14% per year; 257 vs. 203
eaths over a mean 3.5 years of follow-up; hazard ratio
HR] 1.22 [95% CI 1.01–1.46]); there was a similar
ncrease in cardiovascular deaths. The primary outcome of
CCORD (MI, stroke, or cardiovascular death) was re-
uced in the intensive glycemic control group due to a
eduction in nonfatal MI, although this finding was not
tatistically significant when the study was terminated (0.90
0.78–1.04], P  0.16).
Exploratory analyses of the mortality findings of AC-
ORD (evaluating variables including weight gain, use of
ny specific drug or drug combination, and hypoglycemia)
ere unable to identify an explanation for the excess
ortality in the intensive arm (10). In both study arms,
articipants with severe hypoglycemia had higher mortality
han those without severe hypoglycemia. However, there
as a complex interaction between hypoglycemia, study
rm, and mortality: Among participants with at least one
pisode of severe hypoglycemia, mortality was higher in
hose in the standard treatment arm, while among partici-
ants with no history of severe hypoglycemia, mortality was
igher in those in the intensive treatment arm. Other
respecified subset analyses showed that participants with
o previous CVD event and those who had a baseline A1C
8% had a statistically significant reduction in the primary
VD outcome.
The ADVANCE study randomized 11,140 participants
t sites in Europe, Australia/New Zealand, Canada, and
sia to a strategy of intensive glycemic control (with
rimary therapy being the sulfonylurea gliclizide and addi-
ional medications as needed to achieve a target A1C of
6.5%) or to standard therapy (in which any medication
ut gliclizide could be used, with the glycemic target set
ccording to “local guidelines”). ADVANCE participants
required to be at least 55 years of age with either known
ascular disease or at least one other vascular risk factor)
ere slightly older and of similar high CVD risk similar to
hat in ACCORD participants. However, they had an
verage duration of diabetes 2 years shorter, lower baseline
1C (median 7.2%), and almost no use of insulin at
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Glycemic Control and the Prevention of Cardiovascular Events January 20, 2009:298–304nrollment. The median A1C levels achieved in the inten-
ive and standard arms were 6.3 and 7.0%, respectively, and
aximal separation between the arms took several years to
chieve. Use of other drugs that favorably impact CVD risk
aspirin, statins, ACE inhibitors) was lower in ADVANCE
han in ACCORD or VADT.
The primary outcome of ADVANCE was a combination
f microvascular events (nephropathy and retinopathy) and
ajor adverse cardiovascular events (MI, stroke, and car-
iovascular death). Intensive glycemic control significantly
educed the primary end point (HR 0.90 [95% CI 0.82–
able 1. Comparison of the Three Trials of Intensive Glycemic
ACCORD
articipant characteristics
n 10,251
Mean age (years) 62
Duration of diabetes (years) 10
Sex (% male/female) 39/61
History of CVD (%) 35
BMI (kg/m2) 32
Median baseline A1C (%) 8.1
On insulin at baseline (%) 35
rotocol characteristics
A1C goals (%) (I vs. S)* 6.0 vs. 7.0–7.9
Protocol for glycemic control (I vs. S)* Multiple drugs in both arms
Management of other risk factors Embedded blood pressure a
lipid trials
n-study characteristics
Median duration of follow-up (years) 3.5 (terminated early)
Achieved median A1C (%) (I vs. S)* 6.4 vs. 7.5
On insulin at study end (%) (I vs. S)* 77 vs. 55*
On TZD at study end (%) (I vs. S)* 91 vs. 58*
On statin at study end (%) (I vs. S)* 88 vs. 88*
On aspirin at study end (%) (I vs. S)* 76 vs. 76*
Smokers at study end (%) 10
Mean blood pressure at study end (mm Hg)
Intensive glycemic control arm 126/67
Standard glycemic control arm 127/68
Weight changes (kg)
Intensive glycemic control arm 3.5
Standard glycemic control arm 0.4
evere hypoglycemia (participants with one or
more episodes during study) (%)
Intensive glycemic control arm 16.2
Standard glycemic control arm 5.1
utcomes
Definition of primary outcome Nonfatal MI, nonfatal stroke
CVD death
HR for primary outcome (95% CI) 0.90 (0.78–1.04)
HR for mortality findings (95% CI) 1.22 (1.01–1.46)
Medication rates for ACCORD are for any using during the study.
I indicates intensive glycemic control; and S, standard glycemic control..98], P  0.01), although this was due to a significant teduction in the microvascular outcome (0.86 [0.77–0.97],
 0.01), primarily development of macroalbuminuria,
ith no significant reduction in the macrovascular outcome
0.94 [0.84–1.06], P  0.32). There was no increase in
verall or cardiovascular mortality in the intensive compared
ith the standard glycemic control arms (11).
VADT randomized 1,791 participants with type 2 dia-
etes uncontrolled on insulin or maximal-dose oral agents
median entry A1C 9.4%) to a strategy of intensive glycemic
ontrol (goal A1C 6.0%) or standard glycemic control,
ith a planned A1C separation of at least 1.5%. Medication
rol and CVD Outcomes
ADVANCE VADT
11,140 1,791
66 60
8 11.5
42/58 97/3
32 40
28 31
7.2 9.4
1.5 52
6.5 vs. “based on local guidelines” 6.0 (action if 6.5) vs. planned
separation of 1.5
Multiple drugs added to gliclizide vs.
multiple drugs with no gliclizide
Multiple drugs in both arms
Embedded blood pressure trial Protocol for intensive treatment
in both arms
5 5.6
6.3 vs. 7.0 6.9 vs. 8.5
40 vs. 24 89 vs. 74
17 vs. 11 53 vs. 42
46 vs. 48 85 vs. 83
57 vs. 55 88 vs. 86
8 8
136/74 127/68
138/74 125/69
0.1 7.8
1.0 3.4
2.7 21.2
1.5 9.9
Microvascular plus macrovascular
(nonfatal MI, nonfatal stroke,
CVD death) outcomes
Nonfatal MI, nonfatal stroke,
CVD death, hospitalization for
heart failure, revascularization
0.9 (0.82–0.98); macrovascular
0.94 (0.84–1.06)
0.88 (0.74–1.05)
0.93 (0.83–1.06) 1.07 (0.81–1.42)Cont
nd
,reatment algorithms were used to achieve the specified
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January 20, 2009:298–304 Glycemic Control and the Prevention of Cardiovascular Eventslycemic goals, with a goal of using similar medications in
oth groups. Median A1C levels of 6.9 and 8.5% were
chieved in the intensive and standard arms, respectively,
ithin the first year of the study. Other CVD risk factors
ere treated aggressively and equally in both groups, with
he trial achieving excellent blood pressure control, high
evels of aspirin and statin usage, and a high degree of
moking cessation (12).
The primary outcome of VADT was a composite of
VD events (MI, stroke, cardiovascular death, revascular-
zation, hospitalization for heart failure, and amputation for
schemia). During a median 5.6-year follow-up period, the
umulative incidence of the primary outcome was not
ignificantly lower in the intensive arm (HR 0.88 [95% CI
.74–1.05], P  0.12). There were more CVD deaths in
he intensive arm than in the standard arm (38 vs. 29,
udden deaths 11 vs. 4), but the difference was not statisti-
ally significant. Post hoc subgroup analyses suggested that
uration of diabetes interacted with randomization such
hat participants with duration of diabetes less than about
2 years appeared to have a CVD benefit of intensive
lycemic control, while those with longer duration of
isease before study entry had a neutral or even adverse
ffect of intensive glycemic control. Other exploratory anal-
ses suggested that severe hypoglycemia within the past 90
ays was a strong predictor of the primary outcome and of
VD mortality, with an association of severe hypoglycemia
ith all-cause mortality apparent only for participants in the
tandard arm. An embedded ancillary study within the main
ADT showed that baseline coronary or aortic calcium
cores predicted future CVD events and that intensive
lycemic control significantly reduced the primary CVD
nd point in those with low baseline coronary artery calcium
cores but not in those with high baseline scores.
hat Are Potential Explanations for the Increased
VD Deaths With Intensive Glycemic Control
n ACCORD?
umerous post hoc analyses have been unable to prove or
isprove causes; in fact, the design of the study renders such
proof ” elusive. Randomization to the intensive arm was
ssociated with or led to many downstream effects, such as
igher rates of severe hypoglycemia; more frequent use of
nsulin, thiazolidinediones, other drugs, and drug combina-
ions; and greater weight gain. Such factors may be associ-
ted statistically with the higher mortality rate in the
ntensive arm but may not be causative. It is biologically
lausible that severe hypoglycemia could increase the risk of
ardiovascular death in participants with high underlying
VD risk. This might be further confounded by the
evelopment of hypoglycemia unawareness, particularly in
atients with coexisting cardiovascular autonomic neuropa-
hy (a strong risk factor for sudden death). Death from a
ypoglycemic event may be mistakenly ascribed to coronary
rtery disease, since there may not have been a blood glucose
easurement and since there are no anatomical features of Iypoglycemia detected postmortem. Other plausible mech-
nisms for the increase in mortality in ACCORD include
eight gain, unmeasured drug effects or interactions, or the
intensity” of the ACCORD intervention (use of multiple
ral glucose-lowering drugs along with multiple doses of
nsulin, frequent therapy adjustments to push A1C and
elf-monitored blood glucose to very low targets, and an
ntense effort to rapidly reduce A1C by 2% in participants
ntering the trial with advanced diabetes and multiple
omorbidities).
Since the ADVANCE trial did not show any increase in
ortality in the intensive glycemic control arm, examining
he differences between ADVANCE and ACCORD sup-
orts additional hypotheses. ADVANCE participants on
verage appeared to have earlier or less advanced diabetes,
ith shorter duration by 2–3 years and lower A1C at entry
espite very little use of insulin at baseline. A1C was also
owered, even more gradually, in the ADVANCE trial, and
here was no significant weight gain with intensive glycemic
herapy. Although severe hypoglycemia was defined some-
hat differently in the three trials, it appears that this
ccurred in fewer than 3% of intensively treated AD-
ANCE participants for the entire study duration (median
years) compared with16% of intensively treated subjects
n ACCORD and 21% in VADT.
It is likely that the increase in mortality in ACCORD
as related to the overall treatment strategies for intensify-
ng glycemic control in the study population—not the
chieved A1C per se. The ADVANCE study achieved a
edian A1C in its intensive arm similar to that in the
CCORD study, with no increased mortality hazard.
hus, the ACCORD mortality findings do not imply that
atients with type 2 diabetes who can easily achieve or
aintain low A1C levels with lifestyle modifications with or
ithout pharmacotherapy are at risk and need to “raise”
heir A1C.
hy Did None of the Trials Show a Significant
enefit of Intensive Glycemic Control on CVD in
ype 2 Diabetes—in Contrast to Many Epidemiologic
tudies and the DCCT Follow-Up Study?
lthough randomized controlled trials often confirm hy-
otheses grounded in observational evidence or physiologic
tudies of surrogate end points, this is certainly not the first
ime that such trials have failed to do so. The results of
CCORD, ADVANCE, and VADT highlight the critical
eed for randomized controlled trials with meaningful
linical outcomes, such as in these trials, to help answer
ajor clinical questions.
In the three glucose-lowering trials, other CVD risk
actors were treated to a moderate or high degree, and likely
ue to this, all had lower rates of CVD in the standard arm
han originally predicted. The evidence for CVD prevention
y statin therapy, blood pressure treatment, aspirin therapy
n high-risk participants, and other interventions is robust.
n type 2 diabetes, where other CVD risk factors are highly
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Glycemic Control and the Prevention of Cardiovascular Events January 20, 2009:298–304revalent, the additive benefits of intensive glycemic control
ight be difficult to demonstrate except in even larger or
onger trials. It is likely that a real benefit of glucose
owering on CVD in type 2 diabetes, even if it could be
roven, is modest compared with and incremental to treat-
ent of other CVD risk factors.
Additionally, the three trials compared treatments to A1C
evels in the “flatter” part of the observational glycemia-CVD
isk curves (median A1C 6.4–6.9% in the intensive arms
ompared with 7.0–8.4% in the standard arms). Their results
hould not be extrapolated to imply that there would be no
ardiovascular benefit of glucose lowering from very poor
ontrol (e.g., A1C 9%) to good control (e.g., A1C 7%).
All three trials were carried out in participants with
stablished diabetes (mean duration 8–11 years) and either
nown CVD or multiple risk factors, suggesting the pres-
nce of established atherosclerosis. Subset analyses of the
hree trials suggested a significant benefit of intensive
lycemic control on CVD in participants with shorter
uration of diabetes, lower A1C at entry, and/or or absence
f known CVD. The finding of the DCCT follow-up
tudy, that intensive glycemic control initiated in relatively
oung participants free of CVD risk factors was associated
ith a 57% reduction in major CVD outcomes, supports the
bove hypothesis. Of note, the benefit on CVD in the
CCT-EDIC (Epidemiology of Diabetes Interventions
nd Complications) required 9 years of follow-up beyond
he end of the DCCT to become statistically significant.
A recent report (13) of 10 years of follow-up of the
KPDS cohort describes, for the participants originally
andomized to intensive glycemic control compared with
hose randomized to conventional glycemic control, long-
erm reductions in MI (15% with sulfonylurea or insulin as
nitial pharmacotherapy and 33% with metformin as initial
harmacotherapy, both statistically significant) and in all-
ause mortality (13 and 27%, respectively, both statistically
ignificant). These findings support the hypothesis that
lycemic control early in the course of type 2 diabetes may
ave CVD benefit. As is the case with microvascular
omplications, it may be that glycemic control plays a
reater role before macrovascular disease is well developed
nd a minimal or no role when it is advanced.
People with type 1 diabetes, in whom insulin resistance
oes not predominate, tend to have lower rates of coexisting
besity, hypertension, and dyslipidemia than those with type
diabetes yet are also at high lifetime risk of CVD (14). It is
ossible that CVD is more strongly glycemia-mediated in type
diabetes and that intervening on glycemia would ameliorate
VD to a greater extent in type 1 than in type 2 diabetes.
Finally, the inability of ACCORD, ADVANCE, and
ADT to demonstrate significant reduction of CVD with
ntensive glycemic control could also suggest that current
trategies for treating hyperglycemia in patients with more
dvanced type 2 diabetes may have counter-balancing con-
equences for CVD (such as hypoglycemia, weight gain, or
ther metabolic changes). Results of long-term CVD out-ome trials utilizing specific antihyperglycemic drugs, inten-
ive lifestyle therapy (such as the Look AHEAD [Action for
ealth in Diabetes] study), bariatric surgery, or other
merging therapies may shed light on this issue.
hat Are the Implications of These Findings for
linical Care?
he benefits of intensive glycemic control on microvascular
nd neuropathic complications are well established for both
ype 1 and type 2 diabetes. The ADVANCE trial has added
o that evidence base by demonstrating a significant reduc-
ion in the risk of new or worsening albuminuria when
edian A1C was lowered to 6.3% compared with standard
lycemic control achieving an A1C of 7.0%. The lack of
ignificant reduction in CVD events with intensive glycemic
ontrol in ACCORD, ADVANCE, and VADT should not
ead clinicians to abandon the general target of an A1C
7.0% and thereby discount the benefit of good control on
erious and debilitating microvascular complications.
The ADA’s Standards of Medical Care in Diabetes (6)
nd the AHA and ADA’s scientific statement on prevention
15) advocate controlling nonglycemic risk factors (through
lood pressure control, lipid lowering with statin therapy,
spirin therapy, and lifestyle modifications) as the primary
trategies for reducing the burden of CVD in people with
iabetes. The lower-than-predicted CVD rates in AC-
ORD, ADVANCE, and VADT, as well as the recent
ong-term follow-up of the Steno-2 multiple risk factor
ntervention (16), provide strong confirmation of the con-
ept that comprehensive care for diabetes involves treatment
f all vascular risk factors—not just hyperglycemia.
The evidence for a cardiovascular benefit of intensive
lycemic control remains strongest for those with type 1
iabetes. However, subset analyses of ACCORD, AD-
ANCE, and VADT suggest the hypothesis that patients
ith shorter duration of type 2 diabetes and without
stablished atherosclerosis might reap cardiovascular benefit
rom intensive glycemic control. Conversely, it is possible
hat potential risks of intensive glycemic control may out-
eigh its benefits in other patients, such as those with a very
ong duration of diabetes, known history of severe hypogly-
emia, advanced atherosclerosis, and advanced age/frailty.
ertainly, providers should be vigilant in preventing severe
ypoglycemia in patients with advanced disease and should
ot aggressively attempt to achieve near-normal A1C levels
n patients in whom such a target cannot be reasonably
asily and safely achieved.
The evidence obtained from ACCORD, ADVANCE,
nd VADT does not suggest the need for major changes in
lycemic control targets but, rather, additional clarification of
he language that has consistently stressed individualization:
Microvascular disease: Lowering A1C to below or
around 7% has been shown to reduce microvascular and
neuropathic complications of type 1 and type 2 diabetes.
Therefore, the A1C goal for nonpregnant adults in
•t
•
•
w
e
i
c
S
g
A
T
o
A
p
c
P
s
a
M
a
C
E
N
P
t
a
i
r
P
S
m
I
N
i
t
C
f
S
m
i
A
a
a
a
E
g
R
*
†
303JACC Vol. 53, No. 3, 2009 Skyler et al.
January 20, 2009:298–304 Glycemic Control and the Prevention of Cardiovascular Eventsgeneral is 7%. ADA, A-level recommendation; ACC/
AHA, Class I recommendation (Level of Evidence A).*
Macrovascular disease: In type 1 and type 2 diabetes,
randomized controlled trials of intensive versus standard
glycemic control have not shown a significant reduction
in CVD outcomes during the randomized portion of the
trials. However, long-term follow-up of the DCCT and
UKPDS cohorts suggests that treatment to A1C targets
below or around 7% in the years soon after the diagnosis
of diabetes is associated with long-term reduction in risk
of macrovascular disease. Until more evidence becomes
available, the general goal of 7% appears reasonable.
ADA, B level recommendation; ACC/AHA, Class IIb
recommendation (Level of Evidence: A).*
For some patients, individualized glycemic targets other
han the above general goal may be appropriate:
Subgroup analyses of clinical trials such as the DCCT and
UKPDS and the microvascular evidence from the AD-
VANCE trial suggest a small but incremental benefit in
microvascular outcomes with A1C values closer to normal.
Therefore, for selected individual patients, providers might
reasonably suggest even lower A1C goals than the general
goal of 7%, if this can be achieved without significant
hypoglycemia or other adverse effects of treatment. Such
patients might include those with short duration of diabetes,
long life expectancy, and no significant cardiovascular dis-
ease. ADA, B-level recommendation; ACC/AHA, Class
IIa recommendation (Level of Evidence: C).*
Conversely, less stringent A1C goals than the general
goal of 7% may be appropriate for patients with a
history of severe hypoglycemia, limited life expectancy,
advanced microvascular or macrovascular complications,
or extensive comorbid conditions or those with long-
standing diabetes in whom the general goal is difficult to
attain despite diabetes self-management education, ap-
propriate glucose monitoring, and effective doses of
multiple glucose-lowering agents including insulin.
ADA, C-level recommendation; ACC/AHA, Class IIa
recommendation (Level of Evidence: C).*
For primary and secondary CVD risk reduction in patients
ith diabetes, providers should continue to follow the
vidence-based recommendations for blood pressure treatment,
ncluding lipid-lowering with statins, aspirin prophylaxis, smoking
essation, and healthy lifestyle behaviors delineated in the ADA
tandards of Medical Care in Diabetes (6) and the AHA/ADA
uidelines for primary CVD prevention (15).
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PPENDIX 1. DESCRIPTION OF ACC/AHA
VIDENCE GRADING SCHEMA
he recommendations in this statement were originally
eveloped by the American Diabetes Association usingDA’s evidence grading schema. The American College of
ardiology Foundation and the American Heart Associa-
ion applied the ACC/AHA practice guideline evidence-
rading schema as defined below to these recommendations
or the convenience of their readership. Some but not all of
hese recommendations—though approved by the ACCF
nd AHA in this scientific statement—are incorporated
nto the formal ACC/AHA guidelines to date. Future
pdates of ACC/AHA guidelines may include these rec-
mmendations as deemed appropriate by the relevant ACC/
HA writing committees.
ACC/AHA Classification of Recommendations
Class I: Conditions for which there is evidence for
and/or general agreement that a given procedure or
treatment is beneficial, useful, and effective.
Class II: Conditions for which there is conflicting
evidence and/or a divergence of opinion about the
usefulness/efficacy of a procedure or treatment.
Class IIa: Weight of evidence/opinion is in favor of
usefulness/efficacy.
Class IIb: Usefulness/efficacy is less well established by
evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that a procedure/treatment is not
useful/effective and in some cases may be harmful.
ACC/AHA Level of Evidence
Level of Evidence A: Data derived from multiple
randomized clinical trials or meta-analyses.
Level of Evidence B: Data derived from a single
randomized trial or nonrandomized studies.
Level of Evidence C: Only consensus opinion of ex-
perts, case studies, or standard of care.
